Brief: Hansoh Pharmaceutical Says Unit Enters License Agreement With Glenmark For Aumolertinib
16/12/2025 10:09
Dec 16 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: UNIT ENTERS LICENSE AGREEMENT WITH GLENMARK FOR AUMOLERTINIB UNIT TO RECEIVE OVER $1 BILLION IN PAYMENTS AND ROYALTIES DISTRIBUTION AGREEMENT FOR AUMOLERTINIB WITH GLENMARK SPECIALTY S.A. Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion